CD20 role in pathophysiology of Hodgkin’s disease
Open Access
- 1 January 2017
- journal article
- review article
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 63 (9), 810-813
- https://doi.org/10.1590/1806-9282.63.09.810
Abstract
Hodgkin’s lymphoma (HL) is a tumor comprising non-malignant and malignant B-cells. Classical HL expresses CD15+ and CD30+ antigens, and 20 to 40% of patients are CD20+. This antigen is a ligand free protein present in B lymphocyte cells and its function is not well known. Some studies suggest that expression of CD20 may play a major role in Hodgkin’s disease pathophysiology and may affect the patients’ treatment prognosis, as well as relapse and refractory response. In the past few years, development of monoclonal anti-CD20 antibodies changed drastically the treatment for non-Hodgkin lymphomas in which CD20 is expressed. HL treatment is essentially composed of radiotherapy and chemotherapy; however, monoclonal anti-CD20 antibodies applicability is not well delimitated due to lack of information about clinical outcomes with anti-CD20 monotherapy or combined drug therapy using a classic regimen, as well as about CD20 pathophysiology mechanisms in B-cells tumors. The objective of our review is to discuss CD20 function in Hodgkin’s lymphoma development, its influence on disease evolution and outcomes, as well as its effects on therapeutics and patients’ prognostic.Keywords
This publication has 14 references indexed in Scilit:
- Incomplete cytokinesis and re-fusion of small mononucleated Hodgkin cells lead to giant multinucleated Reed–Sternberg cellsProceedings of the National Academy of Sciences, 2013
- Expression of FOXP3, CD68, and CD20 at Diagnosis in the Microenvironment of Classical Hodgkin Lymphoma Is Predictive of OutcomeJournal of Clinical Oncology, 2013
- Hodgkin lymphomaJCI Insight, 2012
- Hodgkin's lymphoma in adultsThe Lancet, 2012
- Hodgkin lymphomaCritical Reviews in Oncology/Hematology, 2012
- Anti-CD20 Antibody Therapy for B-Cell LymphomasNew England Journal of Medicine, 2012
- Off-targeting oft-targeted CD20 in cHLBlood, 2012
- Toward a Personalized Treatment of Hodgkin's DiseaseNew England Journal of Medicine, 2010
- Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trialBlood, 2003
- Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes.Proceedings of the National Academy of Sciences, 1988